A NOVEL NASAL MULTIPLEX DNA-GOLD NANOROD VACCINE against HUMAN PAPILLOMAVIRUS INFECTION

Human papillomavious (HPV) causes cervical cancer, which overwhelmingly affects women in many developing countries. Screening is not provided in these regions, plus the two main protein vaccines are unaffordable and undeliverable in their existing health programs. We investigated the possible DNA vaccine adjuvant vehicle for safe and widespread vaccine delivery and the development of integrated systems to screen women for persistent HPV infection through the intra-nasal immunisation. As the significant expression of 16L1 viral gene in both cell lines and mouse tissues and their reasonable high immunogenicity compared with VLP in mice model, polymer coated gold nanorods driven DNA vaccine could be considered as a promising nasal vaccine against HPV infection. These advantages will further drive down the costs for vaccination and will make male vaccination affordable in the UK and other developed countries in the future. It will likely persuade health authorities in resource-poor countries to implement vaccination as well.